Incyte To Seek Another Monjuvi Approval In Crowded CD19-Targeting Market

Interest Growing Across Indications

 
• By Mandy Jackson

Incyte reported positive topline Phase III results for Monjuvi in relapsed or refractory follicular lymphoma and plans to file for US FDA approval by the end of 2024.

Business candle stick graph chart of stock market investment trading on blue background
Follicular lymphoma may help Monjuvi revenue grow into the hundreds of millions of dollars • Source: Shutterstock

More from Clinical Trials

More from R&D